O2 Innate immune dysregulation drives recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma
British Journal of Dermatology · 23.06.2026 · 195 (1)
DOI: 10.1093/bjd/ljag151.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 23.06.2026. Verfasst von Madalina Alexandru und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and aims Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited, immunologically active, skin disorder, characterized by skin fragility and chronic inflammation, predisposing patients to aggressive early-onset squamous cell carcinoma (cSCC). Despite this, immunopathogenic mechanisms driving tumour progression remain poorly understood, while current treatments fail to address cancer initiation. This study aimed to characterize the RDEB-cSCC innate immune landscape to identify targetable pathways for therapeutic intervention.
Methods
We performed an integrated immune analysis using bulk RNA sequencing of matched nonlesional, perilesional and lesional biopsies as a strategy to model disease progression. This was complemented by peripheral blood immunophenotyping of healthy donors, patients with RDEB and patients with RDEB-cSCC to identify innate immune alterations associated with disease severity. To validate therapeutic targets, a patient-derived three-dimensional immunocompetent spheroid model was established, designed to recapitulate key tumour-promoting immune features, observed in patients with RDEB-cSCC.
Results
Transcriptomic profiling revealed a severity-dependent macrophage enrichment and activation of the immunoregulatory pathway, Janus kinase/signal transducer and activator of transcription (JAK/STAT)3, previously identified as a promising target in RDEB-cSCC. Lesional tissue and patient plasma exhibited concurrent upregulation of both pro- and anti-inflammatory cytokine signatures, indicating a dysregulated immune response. Peripheral immune profiling further revealed a significant shift towards alternatively activated monocytes, expressing CD163 and Tim4, suggesting a prepriming of precursor tumour-associated macrophages, linked to aggressive disease progression. Uniform manifold approximation and projection analysis identified unique monocyte clusters specific to RDEB-cSCC, associated with aggressive tumour behaviour. To functionally validate these tumour-promoting immune features, an immunocompetent spheroid model was developed recapitulating protumour macrophage differentiation and cytokines release associated with JAK/STAT3 activation. Targeting the model with the clinically approved JAK1/2 inhibitor, ruxolitinib, resulted in reduced spheroid growth, increase necrosis and a significant shift in monocyte polarization towards antitumour phenotype.
Conclusions
These findings highlight the innate immune dysregulation as a central driver of RDEB-cSCC, and targeting the monocyte–macrophage plasticity via the JAK/STAT3 pathway could be a potential early intervention strategy for treating RDEB-cSCC.
Zitieren
APA
Alexandru, M., Brooks, I. R., Chen, X., Moravkova, V., Ali, N., McGrath, J. A., Mellerio, J. E., Karagiannis, S. N., & Jacków-Malinowska, J. (2026). O2 Innate immune dysregulation drives recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. British Journal of Dermatology, 195(1). https://doi.org/10.1093/bjd/ljag151.002
Vancouver
Alexandru M, Brooks IR, Chen X, Moravkova V, Ali N, McGrath JA, et al. O2 Innate immune dysregulation drives recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. British Journal of Dermatology. 2026;195(1). doi:10.1093/bjd/ljag151.002
BibTeX
@article{Alexandru2026,
author = {Alexandru, Madalina and Brooks, Imogen R and Chen, Xinyi and Moravkova, Veronika and Ali, Nadira and McGrath, John A and Mellerio, Jemima E and Karagiannis, Sophia N and Jacków-Malinowska, Joanna},
title = {O2 Innate immune dysregulation drives recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma},
journal = {British Journal of Dermatology},
year = {2026},
volume = {195},
number = {1},
doi = {10.1093/bjd/ljag151.002}
}
EUVIMED